How Cell Orchestration Solutions De-Risk and Accelerate Commercial ATMP Delivery Strategies

Cell and Gene Therapies (CGTs), also known as Advanced Therapy Medicinal Products (ATMPs), are transforming traditional pharmaceutical based medicine. Demonstrating significant efficacy in treating and curing genetic disease and disorders, these therapies often address the root cause of the disease rather than treating it symptomatically. As a result, these therapies are seeing significant growth, accelerated development and investment.

In this climate, it’s clear the advantage will rest with developers able to schedule and plan with utmost efficiency and flexibility. This whitepaper focuses on whether partners in the sector will be able to scale development and delivery quickly enough to meet the increasing demands and the inevitable overhaul of supply chain models, and what can be done to help navigate this process.